Lanifibranor

拉尼兰诺

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameLanifibranor
Drug Alias NameIVA-337
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor delta agonistsPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor αPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsDiabetes Mellitus, Type 2Scleroderma, DiffuseMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[28] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesHepalys Pharma IncInventiva SAUniversity Of Florida +[6] 
Inactive CompaniesSolvay Pharmaceuticals
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsScleroderma, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A